Assessment of Potential Substance Abuse Treatment Medications in Nonhuman Primate Models   4

Introduction:

The National Institute on Drug Abuse (NIDA) intends to solicit proposals from qualified organizations (NAICS Code 541715) having in-house capability to provide technical and scientific expertise to determine the effects of compounds in the following paradigms(1) drug discrimination test in nonhuman primates when tested alone or in combination with cocaine, (2) self-administration test in nonhuman primates when tested for ability to reduce cocaine, methamphetamine, or heroin self-administration or to be directly self-administered, and (3) ability to attenuate signs of opioid withdrawal in opioid dependent nonhuman primates.

This project will be utilized by the Division of Therapeutics and Medical Consequences, Addiction Treatment Discovery Program (ATDP), for the purpose of evaluating the efficacy of potential drug abuse treatment medications in non-human primates. Specifically, Rhesus monkeys will be trained in either drug discrimination or self-administration procedures using cocaine or possibly other drugs of abuse. Test compounds will be provided for testing under blinded conditions with information regarding dose, vehicle, and pretreatment time supplied by NIDA. The requirement is to evaluate the effects of the test compound to either substitute or antagonize the discriminative stimulus effects of the training drug, or for its effects on the self-administration dose-effect curve of the training compound using standard protocols to be agreed upon in advance. Standardized, detailed reports with graphs will be prepared and submitted promptly to the program for each compound tested. Approximately five to twelve compounds per year will be tested using drug discrimination procedures, and another five to twelve compounds will be tested using self-administration procedures, as specified by NIDA.

Mandatory Criteria:

Due to the nature of the compounds which will be evaluated under this contract, it is mandatory that offerors possess prior to award US Department of Justice Drug Enforcement Administration (DEA) Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970. In addition, the successful offeror must either possess or demonstrate the ability to obtain prior to award DEA registration for Schedule I controlled substances.

The offeror must demonstrate its understanding and compliance with the NIH Guide for Care and Use of Laboratory Animals. The Offeror shall submit evidence that its proposal was reviewed and approved by the Institution's Animal Care and Use Committee (IACUC). The Assurance number shall be provided with the proposal.

Notice:

We anticipate the award of one cost-reimbursement, level of effort contract for a base period of one year with four one-year options to extend performance. The contract will include additional quantity options.

RFP No. 75N95023R00047 will be available electronically on or about 15 days from the date of this posting. You can access the RFP through the sam.gov (URL: http://sam.gov) or through the NIDA website: (URL: http://www.drugabuse.gov/funding/funding-opportunities/nida-requests-contract-proposals-rfps). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Responses to the RFP will be due 30 days from the release date. NIDA anticipates a December 2023 award date. NIDA will consider proposals submitted by any responsible offeror.

Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.

This advertisement does not commit the Government to award a contract.